28 August 2026
GHK-Cu Research: The Gap Between the Petri Dish and Skin
What is GHK-Cu? Most copper peptide research sits in cell culture, not human skin. The delivery gap, the real evidence, and is GHK-Cu legal in Australia.
Peptides · Healing & Recovery
GHK-Cu
Copper tripeptide-1 · Copper peptide
Cosmetic use widespread · injectable unapproved
A naturally occurring copper-binding tripeptide that declines with age, GHK-Cu is the rare research peptide many Australians already use — it has been a mainstream cosmetic ingredient for decades, with genuine dermatology research behind topical use.
At a glance
- Decades of cosmetic-industry research support topical use
- Controlled studies show improved skin density and photoageing
- Hair-growth evidence is early and mostly preclinical
- Injectable use has essentially no human evidence
How it works
GHK-Cu binds copper and appears to signal tissue remodelling: stimulating collagen and glycosaminoglycan synthesis, supporting wound repair, and modulating inflammation. Topically it acts locally in skin; systemic effects of injected GHK-Cu are far less studied.
What the research shows
Topical GHK-Cu has controlled cosmetic studies showing improvements in skin density, fine lines and photoageing, and a long history in wound-care research. Evidence for hair growth is thinner, and evidence for injectable use in humans is essentially absent.
Regulatory status
Australia
As a cosmetic ingredient, GHK-Cu is legally sold in Australian skincare. Injectable GHK-Cu is a different matter — it is not an approved medicine and is not listed on the ARTG.
Worldwide
Widely permitted as a cosmetic ingredient globally. No injectable GHK-Cu product is approved by the FDA, EMA or comparable regulators.
Latest GHK-Cu articles
27 August 2026
GHK-Cu (Copper Peptide): What the Evidence Shows in Australia
GHK-Cu is the copper peptide already in Australian skincare. What the evidence shows for skin, hair and injections — and where the TGA stands.
This is general information, not medical advice. retatrutide.net.au is an independent publication. Unless stated otherwise above, this compound is not an approved medicine in Australia, and this page does not endorse or facilitate its use. Speak to a registered health practitioner about any treatment decision.
Stay informed
Be first to know.
When it reaches Australia.
Retatrutide is not yet available to the public. But when it is, you will want to be first to know. Sign up to receive:
- The latest clinical trial results and news from Eli Lilly
- Updates on TGA regulatory progress in Australia
- How and where to access Retatrutide when it becomes available
- Occasional information from retatrutide.net.au and our affiliated partners
TGA review expected 2027 — subscribers hear the moment the status changes.
Get the free guide + updates
Enter your details once on our free access guide page — instant download, plus we'll email you the moment there's real news.